grades of recoMMendation and levels of evidence A: Experimental or observational studies of higher consistency. B: Experimental or observational studies of lower consistency. C: Cases reports (non-controlled studies). D: Opinion without critical evaluation, based on consensus, physiological studies or animal models.
oBJective
To advise physicians on the most indicated therapeutic possibilities that can improve the symptoms of the urinary tract and the quality of life of the patient, as well as prevent complications related to the evolution of benign prostatic hyperplasia. Although there are small differences between alpha-blockers, they are all equally effective and lead to a 4-to 6-point objective drop in I-PSS, enough for most patients to report significant improvement in symptoms. These are considered to be very efficient drugs as monotherapy in the treatment of BPH-LUTS. 4 ,5 (A) Patients candidate for monotherapy with alpha-blockers are mainly those with moderate to severe LUTS and with an impact on quality of life. Symptomatic improvement is perceived by the patient within four weeks and may extend over a long period.
3 (A) Alpha-blockers are effective in the treatment of BPH-LUTS, but their mechanism of action does not prevent disease progression, only relief of symptoms. 4, 5 (A) The most common side effects of alpha-blockers are asthenia, dizziness and orthostatic hypotension. 5 (A) Ejaculatory dysfunction (retrograde ejaculation, reduction of seminal ejaculated volume) is frequently reported by patients. 6 (A)
5-alpha-reductase inhibitors (i5ARs)
There are currently two drugs that act by inhibiting 5AR: finasteride and dutasteride. Finasteride is a selective inhibitor of type II isoenzyme, whereas dutasteride is a non-selective inhibitor, affecting type I and II isoenzymes. i5ARs may be prescribed to men with lower urinary tract symptoms and enlarged prostate (> 40 mL) or high prostate-specific antigen (PSA) levels (> 1.6 ng/mL) and may prevent disease progression, reducing both the need for surgery and acute urinary retention. 4, [7] [8] [9] [10] (A) 11 (B) One limitation to the use of monotherapy with i5ARs is the onset of action: improvement of BPH-LUTS takes between 4 and 6 months of therapy. Finasteride and dutasteride have similar efficacy in reducing prostate volume and improving urinary symptoms in BPH. 12 (B) The most relevant adverse effects include decreased libido, erectile dysfunction and ejaculation disorders. One to 2% of the patients develop gynecomastia (enlargement of the breasts with increased breast or nipple sensitivity). 13 (A)
Antimuscarinic drugs
These drugs have the property of inhibiting the action of acetylcholine and thus reducing the contractility of the detrusor muscle. Oxybutynin, tolterodine, darifenacin and solifenacin are currently available in Brazil. Muscarinic receptor antagonists should be considered in men with LUTS who have predominantly vesical storage symptoms. 14 (A) This class of drugs should be used with caution in men with BPH and infravesical obstruction, especially with high post-voidal residual volume, due to the possibility of incomplete emptying and the development of acute urinary retention.
14 (A) Common side effects include dry mouth, constipation, urinary difficulties, nasopharyngitis, dizziness, confusion and restlessness.
Beta-3 agonists
Beta-3 agonists, a new class of drugs for treatment of bladder storage symptoms, stimulates the sympathetic system during bladder filling, promoting relaxation of the detrusor muscle, increasing bladder functional capacity, decreasing urinary frequency and urinary urgency episodes, as well as urinary urge. Since it does not affect the parasympathetic system, there is no interference in detrusor contraction and, thus, in the voiding process, which minimizes the risk of urinary retention. Mirabegron, a beta-3 agonist, did not adversely affect voiding urodynamics (maximum urinary flow and detrusor pressure at maximum urinary flow) compared with placebo after 12 weeks of treatment in a double blind, placebo controlled study.
(A)
Combination therapy (antimuscarinic drugs and alpha-1 blocker) Combination of anticholinergic drugs and alpha-1 blocker may reduce storage symptoms and urinary frequency, according to a long term study. 19 Although it can increase the risk of acute urinary retention in patients with BPH with baseline postvoid volume > 150 mL, the rate of acute urinary retention is reduced in patients with postvoid volume < 150 mL, around 1%. [16] [17] [18] [19] 
Combination therapy (alpha-blocker and i5AR) The combination of alpha-blockers and i5ARs is an effective treatment for patients with moderate to severe LUTS, increased prostate volume (> 40 mL), high PSA (> 1.6 ng/mL), and reduced maximum urinary flow. Combination therapy is valid not only for relief of symptoms but also to reduce the risk of progression of BPH, it means increase of the symptom score, surgical treatment due urinary retention, urinary incontinence, urinary tract infection and renal failure. 4,7-10 (A) 11 (B) It is not recommended for treatment lasting less than one year and should be prescribed with caution in men with suspected infravesical obstruction and high post-voidal residual urine volume. [7] [8] [9] [10] [11] (A) 12 (B). A multicenter, randomized, non-blinded study, that included treatment-naive patients with moderately symptomatic BPH, concluded that a fixed dose of dutasteride/tamsulosin may reduce the risk of clinical progression and improve symptoms compared to expectant treatment, with optional tamsulosin prescription (initiation of protocol-defined therapy if symptoms did not improve). 20 (A)
Phosphodiesterase-5 inhibitors (iPDE5s)
Several studies demonstrate the effect of iPDE5s on the treatment of BPH. [21] [22] [23] [24] (A) The likely mechanisms of action stem from effects on smooth muscle relaxation, endothelial cell proliferation, improved blood flow, and activity on the prostatic efferent nerves. 25 (D) Currently, tadalafil (5 mg once daily) is approved in Brazil for the treatment of urinary symptoms associated with BPH. This indication is based on double-blind randomized placebo-controlled trials (RCT), that showed a significant reduction of I-PSS after twelve weeks. 22, 23, 26, 27 (A) A prospective placebo-controlled study of tadalafil with tamsulosin used as an active comparator showed that tadalafil led to a decrease in tamsulosin-like I-PSS as early as week 1. 23 (A) Since iPDE5 is indicated for the treatment of erectile dysfunction, this class of medication may be an option in the treatment of patients presenting both disorders. 22, 23, 26 (A)
Combination therapy (iPDE5s and alpha-blockers)
The simultaneous use of iPDE5s and alpha-blockers may cause symptomatic hypotension. Such a risk can be reduced with tadalafil, uroselective alpha-blockers (tamsulosin, alfuzosin), low doses of alpha-blockers, separating doses for several hours instead of using them simultaneously, or waiting until the patient is taking a stable dose of a drug to initiate the second one. 28 (D) A systematic review with meta--analysis included seven RCTs [N=515 patients] and evaluated the efficacy of iPDE5s alone or combined with alpha--blockers in the treatment of erectile dysfunction and LUTS, with a follow-up ranging from 60 days to three months. For the treatment of erectile dysfunction, combination therapy produced a statistically significant increase in the International Index of Erectile Function-Erectile Function (IIEF-EF) compared with the group that used iPDE5s alone (MD 2.25, 95CI 0.07-4.43; six trials; Ι²=78%). In the treatment of LUTS, the combination of iPDE5s and alpha-blockers produced statistically significant reductions in I-PSS score (MD -4,21, 95CI -7.09--1.32; five trials; Ι²=93%) and increase in maximum urinary flow (Q max ) [MD 1.43, 95CI 0.38-2.47; four trials; Ι²=0%]. These results should be examined with caution on account of the high heterogeneity between studies for some outcomes, but we can infer that adding iPDE5s to alpha--blockers can improve BPH-LUTS. 29 
(A)
Combination therapy (iPDE5s and i5ARs)
In an RCT with confidence intervals including clinically unimportant differences, 696 men aged ≥ 45 years old and with BPH were randomized to tadalafil 5 mg once daily plus finasteride 5 mg/day or placebo plus finasteride 5 mg/ day for 26 weeks. Prostate symptoms were assessed by I-PSS. At baseline, all patients had I-PSS ≥ 13 points, prostate volume ≥ 30 cc and had never been treated with 5-phosphodiesterase inhibitors. 592 patients (85%) completed the study. Combination therapy (tadalafil + finasteride) compared to finasteride alone reduced the mean I-PSS after 26 weeks by 5.5 points vs. 4.5 points, respectively (minimum mean square error of 1 point, 95CI 0.2-1.9 points). For this comparison, the treatment-related adverse event rate (mild/ moderate) was 31% vs. 27% (p-value was not reported). Combination therapy, compared to finasteride alone, showed patient improvement, but not an overall impression of clinical improvement. 30 (A) Therefore, the addition of tadalafil to finasteride may moderately improve urinary symptoms in men with BPH. 30 (A) The addition of tadalafil to finasteride cannot increase the response to treatment clinically significantly at week 26, based on a post hoc secondary analysis of the RCT described above.
30 (A) Clinically significant response to treatment was defined as a reduction ≥ 3 points or ≥ 25% in the total I-PSS. Comparing the combination therapy (tadalafil + finasteride) with finasteride alone at week 26, the ≥ 3-point reduction in I-PSS was 71.4% vs. 70.2%, respectively (not significant) and the ≥ 25% reduction in I-PSS was 62% vs. 58.3% (not significant). Combination therapy was significantly associated with greater satisfaction with the treatment, in a pre-specified analysis. 31 (B) In a subgroup analysis, also part of this study, including 404 sexually active men, tadalafil plus finasteride was associated with a higher score for erectile function compared to finasteride alone (p<0.001 for all moments analyzed). 30 
